Sanofi, Regeneron post positive results in P3 testing of Libtayo (oncology) monotherapy
Sanofi and Regeneron posted positive results with an overall survival (OS) benefit from the Phase 3 trial investigating its PD-1 inhibitor Libtayo (cemiplimab) monotherapy compared to chemotherapy in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.